201 related articles for article (PubMed ID: 8843316)
21. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.
White TC; Pfaller MA; Rinaldi MG; Smith J; Redding SW
Oral Dis; 1997 May; 3 Suppl 1():S102-9. PubMed ID: 9456667
[TBL] [Abstract][Full Text] [Related]
22. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients.
Revankar SG; Kirkpatrick WR; McAtee RK; Dib OP; Fothergill AW; Redding SW; Rinaldi MG; Patterson TF
J Infect Dis; 1996 Oct; 174(4):821-7. PubMed ID: 8843222
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection].
Ruhnke M; Schmidt-Westhausen A; Trautmann M
Mycoses; 1996; 39 Suppl 2():47-50. PubMed ID: 9198745
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.
Martínez M; López-Ribot JL; Kirkpatrick WR; Bachmann SP; Perea S; Ruesga MT; Patterson TF
J Antimicrob Chemother; 2002 Mar; 49(3):515-24. PubMed ID: 11864952
[TBL] [Abstract][Full Text] [Related]
25. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study.
Vazquez JA; Hidalgo JA; De Bono S
HIV Clin Trials; 2000; 1(3):23-9. PubMed ID: 11590502
[TBL] [Abstract][Full Text] [Related]
26. Clonal and spontaneous origins of fluconazole resistance in Candida albicans.
Xu J; Ramos AR; Vilgalys R; Mitchell TG
J Clin Microbiol; 2000 Mar; 38(3):1214-20. PubMed ID: 10699025
[TBL] [Abstract][Full Text] [Related]
27. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.
Martins MD; Lozano-Chiu M; Rex JH
Clin Infect Dis; 1998 Nov; 27(5):1291-4. PubMed ID: 9827284
[TBL] [Abstract][Full Text] [Related]
28. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Anil S; Ellepola AN; Samaranayake LP
J Oral Pathol Med; 2001 Sep; 30(8):481-8. PubMed ID: 11545239
[TBL] [Abstract][Full Text] [Related]
29. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295.
Fichtenbaum CJ; Zackin R; Rajicic N; Powderly WG; Wheat LJ; Zingman BS
AIDS; 2000 May; 14(7):845-52. PubMed ID: 10839593
[TBL] [Abstract][Full Text] [Related]
30. Relationship between fluconazole dosage regimens and the emergence of fluconazole-resistant Candida albicans.
Goetz MB
AIDS; 1996 Mar; 10(3):335-6. PubMed ID: 8882674
[No Abstract] [Full Text] [Related]
31. Change in fluconazole susceptibility patterns and genetic relationship among oral Candida albicans isolates.
Diaz-Guerra TM; Martinez-Suarez JV; Laguna F; Valencia E; Rodriguez-Tudela JL
AIDS; 1998 Sep; 12(13):1601-10. PubMed ID: 9764778
[TBL] [Abstract][Full Text] [Related]
32. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
[TBL] [Abstract][Full Text] [Related]
33. Random amplification of polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of Candida spp. from human immunodeficiency virus-infected patients on different fluconazole regimens.
Metzgar D; van Belkum A; Field D; Haubrich R; Wills C
J Clin Microbiol; 1998 Aug; 36(8):2308-13. PubMed ID: 9666011
[TBL] [Abstract][Full Text] [Related]
34. [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis].
Eichel M; Just-Nübling G; Helm EB; Stille W
Mycoses; 1996; 39 Suppl 1():102-6. PubMed ID: 8767280
[TBL] [Abstract][Full Text] [Related]
35. Fluconazole-resistant Candida in AIDS patients. Report of two cases.
Heinic GS; Stevens DA; Greenspan D; MacPhail LA; Dodd CL; Stringari S; Strull WM; Hollander H
Oral Surg Oral Med Oral Pathol; 1993 Dec; 76(6):711-5. PubMed ID: 8284074
[TBL] [Abstract][Full Text] [Related]
36. [Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Tapia C; González P; Pereira A; Pérez J; Noriega LM; Palavecino E
Rev Med Chil; 2003 May; 131(5):515-9. PubMed ID: 12879812
[TBL] [Abstract][Full Text] [Related]
37. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy.
Heald AE; Cox GM; Schell WA; Bartlett JA; Perfect JR
AIDS; 1996 Mar; 10(3):263-8. PubMed ID: 8882665
[TBL] [Abstract][Full Text] [Related]
38. Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient.
Thomas-Greber E; Korting HC; Bogner J; Goebel FD
Mycoses; 1994; 37(1-2):35-8. PubMed ID: 7935590
[TBL] [Abstract][Full Text] [Related]
39. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Lopez-Ribot JL; McAtee RK; Kirkpatrick WR; La Valle R; Patterson TF
Clin Diagn Lab Immunol; 1999 Sep; 6(5):665-70. PubMed ID: 10473514
[TBL] [Abstract][Full Text] [Related]
40. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Vazquez JA; Skiest DJ; Nieto L; Northland R; Sanne I; Gogate J; Greaves W; Isaacs R
Clin Infect Dis; 2006 Apr; 42(8):1179-86. PubMed ID: 16575739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
